BIST10013.981,05▼ 0.00%The Tech Renaissance: Can the Magnificent Seven Re-Ignite a Sluggish Market?USD/TRY47.4377▲ 0.20%CHP's Istanbul Event: Kılıçdaroğlu's Clean Politics Message and Market ImplicationsEUR/TRY54.1240▲ 0.30%DABİS Mobile Launch: How It Will Reshape Young Turks' Career ChoicesBTC/USD$64,610.89▲ 0.71%AI Financial Security Risks: New Threat to Credit Card FraudGOLD6.117,09▲ 0.15%Burnham's Devolution Push: Market Reaction in FocusBRENT$88.10▼ 0.00%AI Shopping Revolution: Are We Losing Consumer Trust?Palas Lake Salt Harvest Disrupted by Rainfall: 2,000 Tons of Salt Lost for Local EconomyBIST10013.981,05▼ 0.00%The Tech Renaissance: Can the Magnificent Seven Re-Ignite a Sluggish Market?USD/TRY47.4377▲ 0.20%CHP's Istanbul Event: Kılıçdaroğlu's Clean Politics Message and Market ImplicationsEUR/TRY54.1240▲ 0.30%DABİS Mobile Launch: How It Will Reshape Young Turks' Career ChoicesBTC/USD$64,610.89▲ 0.71%AI Financial Security Risks: New Threat to Credit Card FraudGOLD6.117,09▲ 0.15%Burnham's Devolution Push: Market Reaction in FocusBRENT$88.10▼ 0.00%AI Shopping Revolution: Are We Losing Consumer Trust?Palas Lake Salt Harvest Disrupted by Rainfall: 2,000 Tons of Salt Lost for Local Economy

Global MarketsJuly 19, 2026 at 09:59 AM

TRVI: Haduvio’s $15B Market Potential and TSMC’s Nalbuphine Supply Risks

724FinanceDr. Yaman Ege

TRVI: Haduvio’s $15B Market Potential and TSMC’s Nalbuphine Supply Risks

Trevi Therapeutics (TRVI) shares surged 9.85% after reporting strong clinical trial results for Haduvio, its chronic cough treatment candidate. The company is targeting a $14-15 billion addressable market for chronic cough, which is expected to grow at a 6% CAGR from $9 billion in 2024. TRVI plans to launch a Phase 2b trial for non-IPF ILD-related chronic cough in the second half of 2026. Hedge funds are increasing exposure ahead of potential approval.

TSMC’s supply chain risks in nalbuphine production, coupled with China-US semiconductor tensions, could disrupt TRVI’s timeline. The reliance on rare earth elements from the US threatens production continuity.